A potent broadly neutralizing human RSV antibody targets conserved site IV of the fusion glycoprotein.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 31515478.
- Also identified by DOI 10.1038/s41467-019-12137-1 and PMC identifier 6742648.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Respiratory syncytial virus (RSV) infection is the leading cause of hospitalization and infant mortality under six months of age worldwide; therefore, the prevention of RSV infection in all infants represents a significant unmet medical need. Here we report the isolation of a potent and broadly neutralizing RSV monoclonal antibody derived from a human memory B-cell. This antibody, RB1, is equipotent on RSV A and B subtypes, potently neutralizes a diverse panel of clinical isolates in vitro and demonstrates in vivo protection. It binds to a highly conserved epitope in antigenic site IV of the RSV fusion glycoprotein. RB1 is the parental antibody to MK-1654 which is currently in clinical development for the prevention of RSV infection in infants.
Medical subject headings
- Antibodies, Viral
- Broadly Neutralizing Antibodies
- Conserved Sequence
- Glycoproteins
- Respiratory Syncytial Virus, Human
- Viral Fusion Proteins